Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cymabay Therapeu

CBAY
Current price
32.48 USD +0.01 USD (+0.03%)
Last closed 32.48 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 728 216 832 USD
Yield for 12 month +225.13 %
1Y
3Y
5Y
10Y
15Y
CBAY
21.11.2021 - 28.11.2021

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc. Address: 7601 Dumbarton Circle, Fremont, CA, United States, 94555

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

32.5 USD

P/E ratio

Dividend Yield

Current Year

+31 073 000 USD

Last Year

+31 016 000 USD

Current Quarter

+57 000 USD

Last Quarter

Current Year

+30 392 000 USD

Last Year

-710 000 USD

Current Quarter

+1 000 USD

Last Quarter

-215 000 USD

Key Figures CBAY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -100 998 000 USD
Operating Margin TTM -74557.9 %
PE Ratio
Return On Assets TTM -22.05 %
PEG Ratio
Return On Equity TTM -64.17 %
Wall Street Target Price 32.5 USD
Revenue TTM 31 073 000 USD
Book Value 2.57 USD
Revenue Per Share TTM 0.29 USD
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM -41 635 000 USD
Earnings Share -0.99 USD
Diluted Eps TTM -0.99 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CBAY

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CBAY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CBAY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 110.9792
Price Sales TTM 119.9825
Enterprise Value EBITDA -40.218
Price Book MRQ 12.7567

Financials CBAY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CBAY

For 52 weeks

7.26 USD 32.5 USD
50 Day MA 29.11 USD
Shares Short Prior Month 8 374 129
200 Day MA 19.07 USD
Short Ratio 0.84
Shares Short 5 852 112
Short Percent 5.88 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds


M

MDAXEX

208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics

Metals


Gold

2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics